Navigation Links
BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies

CAMBRIDGE, Mass. and SHENZHEN, China, June 7, 2011 /PRNewswire/ -- Scientists worldwide have been working on the publicly available genomic sequences of the deadly E. coli O104 strain, which is causing the current health crisis in Germany and now spreading throughout Europe. To continue to speed the ongoing international efforts of researchers to assess and halt this growing epidemic, BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released their third version of the assembled genome, which includes new data from this E. coli O104. ( In addition, the FTP site contains a file that provides the PCR primer sequences BGI and its collaborators have used to create diagnostic kits for rapid identification of this highly infectious bacterium.

The new assembly includes more than 200x single-end reads from the Illumina HighSeq Platform, which allowed BGI to provide a more complete genome map and to correct any assembly errors from the previous version. More importantly, this version is a completely de novo assembly, whereas the previous versions by BGI and others used a reference-based assembly method to obtain a consensus sequence. The new assembly continues to support the finding that this infectious strain carries disease-causing genes from two types of pathogenic E. coli: enteroaggregative E. coli (EAEC) and enterohemorrhagic E. coli (EHEC).

Taking advantage of this genomic feature, BGI and the Beijing Institute of Microbiology and Epidemiology researchers have developed a straightforward PCR diagnostic protocol for rapid identification of the outbreak strain. The diagnostic method consists of two pairs of amplification primers that target the enteroaggregative- and hemorrhagic-associated genes (more detailed protocol is available on the BGI FTP site). Diagnostic results can be obtained within 2–3 hours after receiving the sample, and thus will be extremely useful for epidemic surveillance and detection of this bacterium.

BGI has assessed the specificity and sensitivity of this kit and protocol through computational analyses of 4,547 strains (from 2,183 species) using publicly available whole-genome sequences, and through experimental analyses of 323 DNA samples (from 93 species, including 55 E. coli strains that have different phenotypes and the current infectious strain). The findings demonstrated that the kit and protocol have high specificity: no bacterial strain other than E. coli O104 had positive amplification results of both target regions. Sensitivity testing indicated that the kit and protocol could detect this bacterium using a DNA concentration as low as ~1 picogram (10-12 g) in the PCR. Additional validation tests on more patient isolates will be carried out within the week.

NOTE: The complete test protocol for E. coli O104 is available at . Additionally, in a desire to help control the spread of this lethal bacteria, BGI and the Beijing Institute of Microbiology and Epidemiology will provide the designed and synthesized primers free to any disease control and research agency worldwide (contact ). They also continue to call for labs with isolates HUSEC041 (from Germany in 2001) and other 2011 outbreak isolates to understand how the lethal strain originated (

All files previously released on the FTP are available at:

For more information, please refer to the previous news release:

BGI Sequences Genome of the Deadly E. Coli in Germany and Reveals New Super-Toxic Strain


Further analysis on improved genome assembly indicates the outbreak E. Coli has complex genetics with resistance to at least 8 antibiotics


New clues found in tracing the origin of the deadly E coli strain and an appeal for the sharing of additional data


About BGI

BGI (formerly known as Beijing Genomics Institute) was founded in 1999 and has become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation and bio-energy fields, BGI has a proven track record of innovative, high-profile research which has generated over 178 publications in top-tier journals such as Nature and Science. For more information, visit or

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
(Date:10/12/2015)... Okla. , Oct. 12, 2015  Millions of ... free from the shackles of tobacco. An April ... at Kings College London showed electronic cigarettes to be ... smoking. But more than a decade after the technology ... it remained unchanged.    --> ...
(Date:10/12/2015)... , Oct. 12, 2015 ... improve and enhance the quality of images produced ... substances (contrast media) used in magnetic resonance imaging, ... These devices allow the radiologists to interpret the ... conditions of the body. Contrast media can be ...
(Date:10/12/2015)... -- In a Sutter Institute of Medical Research study published ... Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was ... patients in the early, pre-dementia phase of Alzheimer,s disease. ... extracted from the plasma of more than 1,000 blood ... found in patients with Alzheimer,s disease. Sutter Institute of ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... SPH ... has been named the organization’s Executive Vice President of Operations, and three Senior ... key leadership roles in the company. , Debbie Vereb’s appointment to Executive Vice ...
(Date:10/13/2015)... Richmond, Virginia (PRWEB) , ... ... ... American International Biotechnology, LLC presented results from GyencoloGeneTM, the world’s first commercially-available ... at the XXI FIGO World Congress of Gynecology and Obstetrics in Vancouver, ...
(Date:10/12/2015)... Provo, Utah (PRWEB) , ... October 13, 2015 ... ... and corporate training, is proud to announce the release of its new Professional ... course prepares students to use both the ICD-10-CM and ICD-10-PCS code sets, earn ...
(Date:10/12/2015)... CA (PRWEB) , ... October 12, 2015 , ... ... on August 19, 2015, high school aged female athletes, particularly in the ... potentially sidelining repetitive motion and mechanical overuse injuries than male peers in the ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... of San Antonio, Texas recommended that any high-rises in the city limits that do ... going forward. The article explains that it wasn’t until 1982 that the city started ...
Breaking Medicine News(10 mins):